Provectus Announces Acceptance Of Abstract For Poster Presentation At European Society For Medical Oncology 2016 Congress

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Biopharmaceuticals, Inc. (NYSE MKT:PVCT, www.provectusbio.com), a clinical-stage oncology and dermatology biopharmaceutical company ("Provectus" or “The Company”), today announced that the European Society for Medical Oncology’s Scientific Committee has accepted an abstract for a poster presentation detailing the use of PV-10 as a treatment for stage III and IV melanoma as part of ESMO’s 2016 Congress.